Relieves inflammatory and pruritic manifestations of atopic dermatitis. ANDA 91553, held by Padagis Israel. Fluticasone Propionate.
As of Nov 16, 2026, ANDA 91553 (Fluticasone Propionate), held by Padagis Israel, was first approved by FDA on Jul 30, 2013, with 2 approved supplements and 0 published complete response letters.
Fluticasone propionate lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients 3 months of age or older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 30, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluticasone Propionate0.05% · lotion;topical | Fluticasone Propionate | Rx |
| Nov 27, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 27, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 30, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters